Skip to content
What information does the doctor expect from the laboratory? What kind of services can a laboratory deliver to the physician?
12th ECAT International Symposium 2022
Speaker
Titel
Abstract
Presentation
video
M. Coppens /
S. Kitchen
What information does the doctor expect from the laboratory?
What kind of services can a laboratory deliver to the physician?
Related items
Analytical Information :
9
A computer-based model to access costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assay
Minimum citrate tube fill volume for routine coagulation testing
Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays
The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies
Results of a workshop on the inter-laboratory variability of analysis of type 1 factor VIII Inhibitors
The do’s and don’ts of laboratory detection of haemostasis-inhibitors: lessons from a workshop
Comparison of two statistical software programs for determining reference intervals of screening coagulation assays
Analytical performance specifications for hemostasis parameters
The effect of Rivaroxaban on haemostasis assays; results from ECAT surveys
Cases :
13
Prekallikrein deficiency
Effect of high haematocrit levels on coagulation testing
Acquired von Willebrand disease and marginal zone lymphoma
A patient with mild haemophilia A
Lupus Anticoagulant-Hypoprothrombinemia Syndrome
Haemophilia A and treatment, case study
Von Willebrand Jürgens syndrome type I, case study 2016
Von Willebrand Jürgens syndrome type I, case study 2019
Von Willebrand Disease type 2B, case study
A severe haemophilia A patient treated with emicizumab, case study
Acquired haemophilia A
Acquired Hemophilia A, case study
Von Willebrand Disease type 1, case study
ECAT Documents :
67
Von Willebrand Factor (VWF)
Phospholipids
Intrinsic Pathway of Coagulation
Inhibitor
Hemostasis
Hemophilia A
Factor VIII (FVIII)
Desmopressin Acetate (DDAVP)
Contact Activation
Common Pathway of Coagulation
Coagulation Factors
Coagulation Cascade
Coagulation (Clotting)
Bethesda Inhibitor Assay (Titer)
Laboratory issues related to the measurement of efanesoctocog alfa webinar 2025
Activated Partial Thromboplastin Time Test (APTT)
Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: A large international cross-laboratory study
Pre-analytical practices for routine coagulation tests in European laboratories. A collaborative study from the European Organisation for External Quality Assurance Providers in Laboratory Medicine (EQALM)
Analytical variation in factor VIII one‐stage and chromogenic assays: Experiences from the ECAT external quality assessment programme
The results of the workshop on inhibitor testing
Inhibitor testing: positive or negative? True or False?
The laboratory diagnosis of vWD: current insights
Factor VIII Inhibitor Testing, the way to better comparison of test results
Lupus Anticoagulant: Remarkable observations in ECAT surveys
Case studies in Bleeding disorders
How do laboratories interpret unexpected APTT prolongation?
Towards diagnostic quality control: a pilot study on acquired inhibitors
Algoritm for Laboratory Investigations in Case of a prolonged APTT
Measurement of new oral anticoagulans
Factor VIII inhibitor testing – a way to comparable test results
The performance of FVIII and FIX measurement in ECAT surveys
Laboratory assays for the measurement of Factor VIII and IX
Gene therapy, the future in hemophilia treatment?
Pre-analytical Variables in the Hemostasis Laboratory
The role of molecular biology in the diagnosis of impaired haemostasis
Introduction on Inhibitor Testing
ADAMTS13 and the pathogenesis of Thrombotic Thrombocytopenic Purpura (TTP)
Slope and parallelism of APTT dilution curves: new insights
ECAT survey results for low levels of Factor VIII
How to measure low levels of Factor VIII and IX
Bleeding webinar 2021, von Willebrand
The relevance of pre-operative hemostasis screening
Introduction on Inhibitor Testing
Haemophilia, new development in patient treatment
The differential diagnosis between TTP and atypical HUS
The diagnosis of von Willebrand Disease
Developmental haemostasis: consequences for clinical practice
Quality Assurance of extended half-life products
Laboratory measurement of extended half-life FVIII
Potency labelling of extended half-life FVIII en FIX products
Treatmentof patients with extended half-life FVIII and FIX products
The use of snake venoms in the coagulation laboratory
EFLM/EQALM on the laboratory diagnosis of a prolonged APTT
Factor VIII testing: results of ECAT surveys
One-stage clotting assay versus chromogenic testing in the diagnosis of haemophilia patients
Haemophilia treatment and laboratory testing
New developments in haemophilia treatment
Low von Willebrand Factor and diagnostic treshold
Hemophilia and gene therapy
When Haemostasis Assays Mislead
Guidance for FVIII/FIX Inhibitor testing
Impact of COVID-19 pandemic on the quality of test output in haemostasis laboratories
How Do Laboratories Perform von Willebrand Disease Diagnostics and Classification of von Willebrand Disease Patients? Results from External Quality Data and an International Survey
Diagnosis of von Willebrand disease: An assessment of the quality of testing in North American laboratories
Diagnostic Testing for von Willebrand Disease: Trends and Insights from North American Laboratories over the Last Decade
Systematic review and meta-analysis of within-subject and between-subject biological variation data of coagulation and fibrinolytic measurands
International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors
Guidelines :
3
ICSH recommendations for the performance and interpretation of activated partial thromboplastin time and prothrombin time mixing tests
Field Study Evaluating Optimal Interpretation Methods for Activated Partial Thromboplastin Time and Prothrombin Time Mixing Studies (ICSH)
Recommendations for laboratory measurement of factor VIII and FIX type I inhibitors, ICSH recommendations
Haemostatic Cascade :
6
TF Pathway (Extrinsic) with Common Pathway (PT)
Intrinsic Pathway APTT
Coagulation Pathways (All Components)
Activation of TAFI by Thrombin
Activation of Protein C by Thrombin
Activation of Platelets by Thrombin
Quality Issues :
5
Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications
Quality Assurance of replacement therapy and future perspectives
External quality assessment for von Willebrand Factor laboratory analysis
External quality assessment for Factor VIII and Factor IX
The between-laboratoy variation of Factor VIII inhibitor testing
Surveys and Studies :
2
Emicizumab pilot study, part II
Emicizumab pilot study, part I
Questions or suggestions?
Clotpedia Support Form
Submit
Success
